The subsequent expression validation identified a higher TNFRSF14 elevation than PD-L1 in GBM cells after IFN-γ treatment, instead of IFN-α or IFN-β exposure, which complied with a dose-dependent manner. This evidence concerns the gene TNFRSF14 and glioblastoma.